In addition, we conducted subgroup analyses to explore the differences in the efficacy of extended adjuvant pyrotinib across different prior adjuvant regimens, including trastuzumab plus pertuzumab or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback